Jefferies Group Comments on Sanofi SA’s FY2019 Earnings (SNY)

Sanofi SA (NYSE:SNY) – Investment analysts at Jefferies Group issued their FY2019 earnings per share estimates for shares of Sanofi in a research report issued to clients and investors on Tuesday. Jefferies Group analyst J. Holford expects that the company will post earnings of $3.78 per share for the year. Jefferies Group also issued estimates for Sanofi’s FY2020 earnings at $4.14 EPS and FY2021 earnings at $4.47 EPS.

Sanofi (NYSE:SNY) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $1.00 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.00. Sanofi had a net margin of 25.44% and a return on equity of 25.19%.

A number of other research analysts have also recently issued reports on the stock. Bank of America cut shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 6th. Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. Morgan Stanley cut shares of Sanofi from an “overweight” rating to an “underweight” rating in a research note on Friday, December 1st. Barclays raised shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Thursday, December 14th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $51.50.

Shares of Sanofi (NYSE SNY) traded down $0.09 during trading hours on Thursday, reaching $44.51. 1,864,658 shares of the company were exchanged, compared to its average volume of 1,260,000. The company has a market capitalization of $112,610.00, a PE ratio of 20.23, a price-to-earnings-growth ratio of 2.56 and a beta of 0.86. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16. Sanofi has a fifty-two week low of $39.42 and a fifty-two week high of $50.65.

Several hedge funds and other institutional investors have recently bought and sold shares of SNY. BlackRock Inc. grew its stake in shares of Sanofi by 47.6% during the second quarter. BlackRock Inc. now owns 2,235,422 shares of the company’s stock worth $107,100,000 after buying an additional 720,523 shares during the last quarter. UBS Asset Management Americas Inc. grew its stake in shares of Sanofi by 22.7% during the second quarter. UBS Asset Management Americas Inc. now owns 75,475 shares of the company’s stock worth $3,616,000 after buying an additional 13,959 shares during the last quarter. FMR LLC grew its stake in shares of Sanofi by 3.0% during the second quarter. FMR LLC now owns 5,374,385 shares of the company’s stock worth $257,487,000 after buying an additional 155,751 shares during the last quarter. MML Investors Services LLC grew its stake in shares of Sanofi by 18.6% during the second quarter. MML Investors Services LLC now owns 39,654 shares of the company’s stock worth $1,900,000 after buying an additional 6,215 shares during the last quarter. Finally, Horizon Investments LLC bought a new stake in shares of Sanofi during the second quarter worth $951,000. 9.08% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Jefferies Group Comments on Sanofi SA’s FY2019 Earnings (SNY)” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/18/jefferies-group-comments-on-sanofi-sas-fy2019-earnings-sny.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Earnings History and Estimates for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply